Patents by Inventor Helen M. THACKRAY

Helen M. THACKRAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS
    Publication number: 20230414641
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 28, 2023
    Applicant: GlycoMimetics, Inc.
    Inventors: Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
  • Methods for treating acute myeloid leukemia and related conditions
    Patent number: 11707474
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 25, 2023
    Assignee: GlycoMimetics, Inc.
    Inventors: Helen M. Thackray, Henry H. Flanner, Curt D. Wolfgang
  • METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES
    Publication number: 20220265691
    Abstract: Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome. Interestingly, relapsed/refractory acute myeloid leukemia (AML) patients expressing high levels of sialyl Lex on their blasts show the greatest therapeutic response when treated with the E-selection inhibitor compound of Formula I. Transcriptome profiling of E-selectin ligand-forming glycosylation genes showed that ST3GAL4 and FUT7 were consistently expressed in the majority of cancers evaluated. Poor survival outcomes of FLT3-mutated AML patients that express high levels of ST3GAL4 and FUT7 implicated E-selectin in this disease state. These genes may be predictive biomarkers in AML patients. Methods of treatment of cancer comprising screening AML patients for expression of genes that contribute to the synthesis of the E-selectin ligand sialyl Lex, then treating those patients with an E-selection inhibitor, are disclosed.
    Type: Application
    Filed: July 12, 2020
    Publication date: August 25, 2022
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, William E. FOGLER, Helen M. THACKRAY, Eric J. FELDMAN, David STEWART
  • METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS
    Publication number: 20210069220
    Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
    Type: Application
    Filed: March 4, 2019
    Publication date: March 11, 2021
    Inventors: Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG